Wholeheartedly agree, LL is multi-faceted and can
Post# of 153167
What I was trying to get at for at least solid tumor oncology, how our MOA works we don't have to look at it that we need larger pharmaceutical companies, its more they need us to be more effective and competitive.
That change in perspectives changes things IMO. In that regard, we are sitting on the same side of the table as the big companies rather than across the table as just another stand alone therapy with potential. If we synergize with their products to make people live longer, and even cure, then marketing, sales, etc. would need to synergize with us to stay competitive. Meaning, again IMO, marketing, sales, awareness, knowledge, additional research with their products, will be "pulled" thru the supply chain by them to the doctor and patient markets because they need us to keep up with all the other therapies we enhance.
It was an eye-opening epiphany for me.
IMO

